H.C. Wainwright lowered the firm’s price target on Emergent BioSolutions (EBS) to $12 from $15 and keeps a Buy rating on the shares following the earnings miss. The firm cites lowered earnings expectations for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Adds Independent Director Amid Turnaround Efforts
- Emergent BioSolutions appoints Fowler to board of directors
- Emergent BioSolutions sees FY26 revenue $720M-$760M, consensus $809.4M
- Emergent BioSolutions sees Q1 revenue $135M-$155M, consensus $275M
- Emergent BioSolutions reports Q4 EPS (43c) vs. 5c last year